Clinical trial · Observational
Epidemiology of TNBC in Asyut Clinical Oncology Department
Epidemiology of Triple Negative Breast Cancer in Asyut Clinical Oncology Department From 2015 to 2022 ( A Hospital Based Study)
NCT05586659CI-TRIAL-00061533unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Epidemiological Study about behavior of TNBC in Clinical oncology department in 8 y in Asyut university hospital
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Incidence of TNBC
- timeFrame
- Baseline
- description
- Incidence of TNBC in clinical oncology department from 2015-2022
- measure
- Behavior of the disease and stage
- timeFrame
- baseline
- description
- Behavior of the disease and stage of presentation
- measure
- Types of treatment
- timeFrame
- baseline
- description
- Types of treatment
Secondary outcomes (3)
- measure
- DFS
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:- Age ≥ 18 * Male or female * Diagnosed as TNBC from ( 2015- 2022 ) confirmed by pathology * Adjuvant or metastatic Exclusion Criteria:- Have other type of malignancy * HER2 , ER, PR positive
References
Publications (2)
- BACKGROUNDWolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013 Nov 1;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984. Epub 2013 Oct 7. PMID 24101045
- BACKGROUNDLin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008 Nov 15;113(10):2638-45. doi: 10.1002/cncr.23930. PMID 18833576